- Becton Dickinson and Co (NYSE:BDX) will sell Accelerate Diagnostics Inc’s (NASDAQ:AXDX) rapid testing solution for antibiotic resistance and susceptibility, offering results in hours versus one to two days with some traditional laboratory methods.
- Becton Dickinson will market and sell the Accelerate Pheno system and Accelerate Arc module and associated test kits through its global sales network.
- These solutions complement BD’s existing Clinical Microbiology portfolio.
- The Accelerate PhenoTest BC kit is the first test cleared by the FDA to deliver both rapid identification and phenotypic antibiotic susceptibility results in hours direct from positive blood cultures.
- The Accelerate Arc module is a simple load-and-go system.
- Accelerate Diagnostics reported Q2 sales of $3.9 million, +39% Y/Y beating the consensus of $3 million, driven by increased capital and recurring revenues.
- The company added eight contracted instruments and brought three instruments live in the U.S. in the quarter.
- It ended the quarter with 316 U.S. clinically live, and revenue-generating instruments, with another 78 U.S. contracted instruments in the process of being implemented and not yet revenue-generating.
- The company reported an EPS loss of $(0.23), down from $(0.36) a year ago and beating the consensus loss of $(0.28).
- Price Action: AXDX shares are up 22.2% at $2.59 during the market session on the last check Monday.
Why Western Alliance Stock (WAL) Is Down 5% Today
Western Alliance Bancorporation (NYSE: WAL) shares are trading lower by 4.8% to $48.55 during Tuesday's session.
